This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts Believe Select Medical (SEM) Could Rally 75%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 74.5% upside potential for Select Medical (SEM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The Joint (JYNT) Acquires 4 Franchised Facilities, Down 5%
by Zacks Equity Research
The Joint (JYNT) anticipates the new acquisition value in Scottsdale to match the price of its previous purchases.
Humana (HUM) Expands JV, To Invest $1.2B, Eyes 100 New Clinics
by Zacks Equity Research
Through the first JV, Humana (HUM) and its partner are pumping $800 million into developing 67 facilities by early 2023.
Wall Street Analysts Think Select Medical (SEM) Could Surge 91%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Select Medical (SEM) points to a 91.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Select Medical (SEM) Shares Up on Q1 Earnings & Revenue Beat
by Zacks Equity Research
Select Medical's (SEM) first-quarter earnings benefit from higher patient visits and sound segmental contributions to revenues, partly offset by elevated labor expenses.
Select Medical (SEM) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of 27.59% and 2.96%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Molina (MOH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 3.38% and 3.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) to Open 31-Bed Hospital in Northern Ohio
by Zacks Equity Research
The new facility is likely to be a satellite unit of Select Medical Holdings' (SEM) Regency Hospital Toledou, located in Sylvania, OH.
Select Medical (SEM) Q4 Earnings Beat on Higher Admissions
by Zacks Equity Research
Select Medical's (SEM) fourth-quarter results reflect solid revenues driven by robust contributions from all its segments, partly offset by higher costs and expenses.
Select Medical (SEM) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of 27.59% and 0.07%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Select Medical (SEM) Q4 Earnings Expected to Decline
by Zacks Equity Research
Select Medical (SEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Centene (CNC) Q4 Earnings Beat Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 3.06% and 0.12%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) '21 Sales View Up, Labor Costs Ail Profits
by Zacks Equity Research
Select Medical Holdings (SEM) estimates net operating revenues for 2021 to be $6.2 billion, up from the previous expectations.
Humana (HUM) to Buy Back Shares of $1B to Add Shareholder Value
by Zacks Equity Research
Humana (HUM) to buy back shares worth $1 billion as part of its $3-billion share repurchase plan announced in February 2021. This suggests its commitment toward delivering a long-term shareholder value.
Why Seasoned Investors are Retaining Community Health (CYH)
by Zacks Equity Research
Community Health Systems (CYH) is focused on making strategic acquisitions to boost its business through inorganic growth.
Select Medical's (SEM) Rising Stake in Concentra to Aid
by Zacks Equity Research
Select Medical Holdings (SEM) acquires the remaining Concentra stake from equity holders for $625.6 million.
Centene vs. Anthem: Which is a Better-Positioned Stock?
by Zacks Equity Research
Centene (CNC) and Anthem (ANTM) are poised to grow in the prospering health insurance industry. On comparative evaluation, we try to discover which stock is more profitable, based on the fundamentals.
Community Health (CYH) Up 64% YTD: More Growth Potential Left?
by Zacks Equity Research
Community Health Systems' (CYH) cost-control initiatives are likely to lower costs to a great extent and boost the bottom line.
Why Seasoned Investors are Retaining Select Medical (SEM) Stock
by Zacks Equity Research
Select Medical (SEM) is focused on making strategic acquisitions to boost its business through inorganic growth.
Select Medical (SEM) Q3 Earnings Beat, Hikes '21 EPS View
by Zacks Equity Research
Select Medical's (SEM) third-quarter results reflect solid revenues driven by strong segmental contributions, and an uptick in admissions and patient visits, partly offset by elevated costs.
Analysts Estimate Select Medical (SEM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Select Medical (SEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Encompass Health (EHC) Rides on Solid Revenues, Expansion Plans
by Zacks Equity Research
Encompass Health (EHC) continues to gain, courtesy of sustained growth in revenues, sound expansion endeavors across the United States and a robust 2021 business outlook.
Here's Why Select Medical (SEM) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Hold Onto Select Medical (SEM) Now
by Zacks Equity Research
Select Medical (SEM) is a long-term player on the back of its leadership position in acute care services.
Centene vs. Anthem: Which is a Better-Positioned Stock?
by Zacks Equity Research
Centene (CNC) and Anthem (ANTM) are poised to grow in the thriving health insurance industry. On comparative evaluation, we try to discover which stock is more profitable, based on the fundamentals.